Edition:
United States

Abiomed Inc (ABMD.OQ)

ABMD.OQ on NASDAQ Stock Exchange Global Select Market

267.74USD
16 Feb 2018
Change (% chg)

$6.70 (+2.57%)
Prev Close
$261.04
Open
$261.26
Day's High
$268.56
Day's Low
$260.02
Volume
158,771
Avg. Vol
131,353
52-wk High
$268.56
52-wk Low
$110.61

Chart for

About

ABIOMED, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops,... (more)

Overall

Beta: 0.27
Market Cap(Mil.): $11,838.43
Shares Outstanding(Mil.): 44.22
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 46.02 17.27
EPS (TTM): -- -- --
ROI: -- 9.08 35.43
ROE: -- 13.32 17.10

BRIEF-Abiomed Receives Approval For Expanded FDA Indication For High Risk PCI Procedures

* ABIOMED RECEIVES APPROVAL FOR EXPANDED FDA INDICATION FOR HIGH RISK PERCUTANEOUS CORONARY INTERVENTION (PCI) PROCEDURES Source text for Eikon: Further company coverage:

Feb 14 2018

BRIEF-Abiomed Receives Approval For Expanded FDA Indication For Cardiomyopathy With Cardiogenic Shock

* ABIOMED RECEIVES APPROVAL FOR EXPANDED FDA INDICATION FOR CARDIOMYOPATHY WITH CARDIOGENIC SHOCK

Feb 13 2018

BRIEF-Abiomed Q3 Gaap Earnings Per Share $0.29

* ABIOMED ANNOUNCES Q3 FY 2018 RECORD REVENUE OF $154 MILLION, UP 34% OVER PRIOR YEAR

Feb 01 2018

BRIEF-Abiomed Reports Q3 Adjusted Earnings Per Share $0.70

* ABIOMED ANNOUNCES Q3 FY 2018 RECORD REVENUE OF $154 MILLION, UP 34% OVER PRIOR YEAR

Feb 01 2018

BRIEF-Abiomed Reports Preliminary Q3 FY 2018 Revenue Of $154 Mln, Up 34 Pct Over Prior Year

* ABIOMED ANNOUNCES PRELIMINARY Q3 FY 2018 REVENUE OF $154 MILLION, UP 34% OVER PRIOR YEAR

Jan 08 2018

BRIEF-Abiomed Q2 earnings per share $0.54

* Abiomed announces Q2 fy 2018 revenue of $132.8 million, up 29% and record u.s. Patient utilization, up 33 pct

Oct 26 2017

Abiomed invests in Israeli medical device maker Magenta

JERUSALEM Israeli medical device company Magenta Medical said on Thursday it has raised $15 million in funding led by Massachusetts-based Abiomed Inc, a maker of catheter-based heart pumps, and venture capital firm Pitango.

Sep 28 2017

Abiomed invests in Israeli medical device maker Magenta

JERUSALEM, Sept 28 Israeli medical device company Magenta Medical said on Thursday it has raised $15 million in funding led by Massachusetts-based Abiomed Inc , a maker of catheter-based heart pumps, and venture capital firm Pitango.

Sep 28 2017

BRIEF-Abiomed receives FDA PMA approval for Impella RP for right heart failure

* Abiomed receives FDA PMA approval for Impella RP for right heart failure Source text for Eikon: Further company coverage:

Sep 20 2017

BRIEF-Abiomed maintains fiscal year 2018 revenue guidance

* Says ‍is maintaining its fiscal year 2018 revenue guidance of $560 million to $575 million - SEC filing​

Aug 28 2017

Earnings vs. Estimates